Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
, 74 (2), 93-118

[Psychopharmacology of Anxiety and Depression: Historical Aspects, Current Treatments and Perspectives]

[Article in French]
Affiliations
Review

[Psychopharmacology of Anxiety and Depression: Historical Aspects, Current Treatments and Perspectives]

[Article in French]
H Javelot. Ann Pharm Fr.

Abstract

Pharmacological treatment of acute anxiety still relies on benzodiazepines, while chronic anxiety disorders and depression are treated with different antidepressants, according to specific indications. The monoaminergic axis is represented by two families which are being developed: (i) serotonin-norepinephrine-dopamine reuptake inhibitors (SNDRI), also called triple reuptake inhibitors (TRI), for the treatment of depression (amitifadine), (ii) multimodal antidepressants for depression and anxiety disorders (generalized anxiety disorder mainly) (tedatioxetine, vortioxetine and vilazodone). Third-generation antipsychotics (aripiprazole, lurasidone, brexpiprazole, cariprazine) appear relevant in the treatment of resistant depression and some anxiety disorders. Among the modulators of the glutamatergic axis, promising compounds include: (i) ionotropic regulators of NMDA receptors: esketamine, AVP-923 and AVP-786, CERC-301, rapastinel (Glyx-13), NRX-1074 developed for depression, rapastinel and bitopertine developed for obsessive compulsive disorder, (ii) metabotropic glutamate receptors modulators: decoglurant and basimglurant developed for depression and mavoglurant developed for obsessive compulsive disorder.

Keywords: Anxiety; Anxiété; Depression; Dépression; New treatments; Nouveaux traitements.

Similar articles

See all similar articles

Cited by 2 articles

MeSH terms

LinkOut - more resources

Feedback